Skip to main content
PLOS ONE logoLink to PLOS ONE
. 2024 Apr 18;19(4):e0302235. doi: 10.1371/journal.pone.0302235

Feasibility and preliminary effects of a mindfulness-based physical exercise (MBPE) program for community-dwelling older people with sarcopenia: A protocol for a parallel, two-armed pilot randomised controlled trial

Meng-Li Li 1, Patrick Pui-Kin Kor 1,*, Zhi-Ying Zhang 2, Justina Yat-Wa Liu 1
Editor: Meryem Merve Ören Çelik3
PMCID: PMC11025830  PMID: 38635544

Abstract

Introduction

Physical exercise (PE) is essential for alleviating the symptoms of sarcopenia. Low motivation is a major barrier to PE. Mindfulness-based intervention (MBI) has the potential to improve motivation. However, few studies have used a mindfulness-based PE (MBPE) intervention among older people with sarcopenia.

Objectives

To assess the feasibility, acceptability and preliminary effects of the MBPE program among community-dwelling older people with sarcopenia.

Methods and analysis

A two-arm pilot randomised controlled trial will be conducted to assess the feasibility, acceptability and preliminary effects of an MBPE program among community-dwelling older people with sarcopenia. A total of 60 participants will be randomised into the intervention group, receiving the MBPE intervention twice a week over 12 weeks, or the control group, receiving health education with the same duration, number of sessions and frequency as the intervention group. Each session of the MBPE program will last about 60 min, including 5-10- min introduction, 20-min MBI, 30-min PE and 5-10-min sharing and discussion. The primary outcomes will be the feasibility (i.e., the time spent recruiting participants, the eligibility rate and the recruitment rate) and acceptability (i.e., the attendance rate, completion rate and attrition rate) of the MBPE program. The secondary outcomes will be the preliminary effects of the MBPE program on symptoms of sarcopenia, motivation for PE, psychological well-being, mindfulness level, physical activity level and quality of life. Individual interviews will be conducted to identify the strengths, limitations and therapeutic components of the intervention. The quantitative data will be analysed by generalised estimating equations. The qualitative data will be analysed by Braun and Clarke’s thematic approach.

Conclusion

The findings of this study will be able to provide evidence for the health professionals in adopting MBPE as a supportive intervention for the older adults with sarcopenia and the groundworks for the researchers in developing non-pharmacological intervention for older adults. The positive effects could facilitate healthy ageing and relief the burden of the medical system, especially in the countries facing the ageing population.

Trial registration number

NCT05982067; ClinicalTrials.gov.

Introduction

Sarcopenia is a progressive and generalised skeletal muscle disorder characterised by decreased muscle mass, muscle strength and physical function [1]. It is classified as an independent disease with the code ICD-10-CM (M62.84) by the World Health Organization [2]. Globally, it is estimated that over 120 million older adults are living with sarcopenia, and this number is expected to double by 2050 [3, 4]. Compared with healthy ageing, sarcopenia significantly increases the risks of various adverse health events, such as falling by 3.23 times, fracture by up to 3.75 times [5], hospitalisation by 2.07 times [6] and all-cause mortality by 2.20 times [7] and it is also negatively associated with psychological well-being [8]. Sarcopenia greatly increases healthcare costs and burden in medical system [9]. Thus, it is imperative to find a way to manage sarcopenia in order to promote healthy ageing worldwide.

Currently, there are no approved medications for treating sarcopenia [10]. Lifestyle interventions, especially physical exercise (PE) interventions, have been demonstrated to mitigate the symptoms of sarcopenia [1115]. Thus, PE is strongly recommended as the first-line treatment [16]. However, the low adherence and motivation to regular PE is a major concern in older adults with sarcopenia [17]. A systematic review (SR) demonstrated that the adherence to PE interventions by healthy older adults was approximately 60% [18]. The adherence of older adults with sarcopenia might be even lower than 60% due to their decreased physical function, PE ability and mobility [19]. This problem has been extensively investigated in numerous prior studies [2023], but effective interventions and management have not been adequately addressed or explored in the existing literature.

Distraction, mind-wandering and negative thoughts and feelings, such as fatigue, anxious or hopeless during the PE, were the common barriers affecting the motivation among the older adults with sarcopenia in performing PE, in addition to physical function and supervision [24, 25]. For example, study has indicated that older adults with sarcopenia are easily derailed by issues in daily life [26] and misled by their preconceived misunderstandings about PE, such as the belief that they are too old to perform any kind of PE [20]. The PRIME (Plans, Impulses, Inhibitions, Motivations, Evaluations and Response) theory of motivation (S1 Fig, details in Conceptual framework of the MBPE program section) explained diversity of factors that influence motivation and emphasized the positive feelings and non-judgmental self-awareness for engaging people in goal-directed behaviour [25, 27]. Although prior studies adopted various strategies to improve adherence and motivation to PE for the older adults with sarcopenia [12], only a few of them took these components (e.g., distraction, negative feelings) into consideration when designing the PE program. Moreover, as the above negative feelings and experiences of older adults with sarcopenia regarding PE are also likely to undermine their psychological well-being and may lead to mental health issues (e.g., anxiety, depression) [28]. Therefore, a way to promote the positive feelings and non-judgmental self-awareness to enhance their motivation in performing PE and ultimately improve their physical health as well as psychological well-being is urgently required.

Mindfulness is defined as a process of openly attending with awareness to one’s present moment [29]. Mindfulness-based intervention (BMI) is primarily designed for treating depression and other mental health problems [30, 31]. Additionally, an increasing number of studies have demonstrated its positive effects in enhancing the PE levels in different populations [3234]. One SR [35] concluded that MBIs effectively activated the motivation to perform PE and the adherence to PE in older adults, and a 4-week RCT [36] reached a similar conclusion. Moreover, the adherence to MBI can be maintained even after the program has ended [37]. The mindful coping model (S2 Fig) offers a possible explanation of the positive effects in which the MBI direct the participants’ attention away from their negative thinking, enhance their engagement in the daily activities and PE and evoking positive feelings [38]. This implies that MBIs could be incorporated into PE interventions to improve both the adherence to PE and the psychological well-being of older adults with sarcopenia.

However, despite the benefits of MBIs, few studies of mindfulness embedded into PE interventions for older adults with sarcopenia older people have been conducted. To the best of our knowledge, only two mindfulness-based PE interventions (MBPE) have been conducted in this population, adopting mindful yoga education [39] and Tai Chi [40]. However, limitations exist in these two studies, focusing solely on women [39] or solely on men aged 85 years or older [40], not assessing muscle mass [39, 40], even though muscle loss is a key symptom of sarcopenia. Importantly, neither of these studies included resistance exercise, which is the most highly recommended type of PE to treat sarcopenia [16]. It is imperative to develop a novel intervention combining MBI and PE (specifically resistance exercise) to activate and improve the motivation for and adherence to PE, mitigate sarcopenia and improve psychological well-being in older adults with sarcopenia. Given the limited evidence in this field, this pilot RCT aims to explore the feasibility, acceptability and preliminary effects of a MBPE intervention in community-dwelling older people with sarcopenia.

Objectives and hypothesis

The objectives of this pilot RCT are as follows: (1) to assess the feasibility and acceptability of the MBPE program among community-dwelling older people with sarcopenia; and (2) to investigate the preliminary effects of the MBPE program on the symptoms of sarcopenia, motivation for PE, psychological well-being, mindfulness level, physical activity level and quality of life among this population.

We hypothesise that the MBPE program is acceptable and feasible with the potential to improve the motivation, adherence to PE, physical and psychological health of the older adults with sarcopenia.

Methods and analysis

Study design

This study will adopt a two-arm pilot RCT design with nested individual interviews. The Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) guideline [41] is followed in this proposal (Fig 1 and S1S3 Appendices). The overall flow of the pilot RCT in the form of a Consolidated Standards of Reporting Trials (CONSORT) diagram is shown in Fig 2 [42]. The conceptual framework of this study is shown in Fig 3.

Fig 1. The SPIRIT flow of the mindfulness-based physical exercise program.

Fig 1

Fig 2. CONSOROT diagram of the mindfulness-based physical exercise program.

Fig 2

Fig 3. The conceptual framework of the mindfulness-based physical exercise program.

Fig 3

Study setting

Participants will be recruited from three community health care centres (CHCCs) in Suzhou, Jiangsu province, China. The MBPE intervention will be conducted at one of the CHCCs and at participants’ homes.

Eligibility criteria

This study will focus on community-dwelling older people with sarcopenia. The detailed inclusion and exclusion criteria are given in Table 1.

Table 1. Eligibility criteria for participants.

Inclusion criteria
1. Community-dwelling and aged 60 years or older.
2. Diagnosed with sarcopenia according to the criteria of the Asian Working Group for Sarcopenia (AWGS) [43]:
  • a)

    decreased muscle strength: handgrip strength of men < 28 kg; handgrip strength of women < 18 kg;

  • b)

    or decreased physical performance: 5-time chair-stand test time ≥12 s;

  • c)

    or decreased muscle mass: skeletal muscle mass index (SMI) of men < 7.0 kg/m2; SMI of women < 5.7 kg/m2.

3. Able to communicate orally and in writing and understand instructions.
Exclusion criteria
1. Hospitalisation lasting for more than 5 days in the 3 months prior to recruitment.
2. Unable to undergo body composition test, due to having a heart pacemaker, vascular stent, steel plates or other materials in the body.
3. Contraindications to PE, such as severe musculoskeletal disorders, severe cardiovascular diseases or spinal nerve injury.
4. Already undertaking regular PE: 150 min of moderate-intensity activity or 75 min of vigorous-intensity activity per week in the 3 months prior to recruitment [44].
5. Practising mindfulness/yoga for >45 min a week in the 6 months prior to recruitment [45].

Sample size

25 per group will provide sufficient information for planning the proposed subsequent main randomised trial with an anticipated standardised effect size of about 0.2 on the primary outcome, handgrip strength [46]. Considering a 20% attrition rate [47], the sample size of this pilot RCT has been calculated as 25 × (1 + 20%) = 30 in each group.

Allocation and blinding

After they give their informed consent, eligible participants will be randomised into the intervention group (IG) or the control group (CG) with a 1:1 ratio. Block randomisation with a block size of 4 will be used to balance the numbers in each group. Three research assistants who will not otherwise be involved in this study will perform the randomisation independently to ensure allocation concealment and avoid selection bias. The random numbers will be generated by a computer and sealed in opaque envelopes and delivered to each participant.

Due to the characteristics of the interventions (the MBPE vs health education), it will be impossible to blind the participants and interventionists. The following personnel will, however, be blinded: the research assistants recruiting participants, the research assistants performing randomisation and the outcome assessor.

Intervention development

The detailed development of the MBPE program follows the Medical Research Council (MRC) guideline for complex interventions development [48], which considered the findings from our SR [49], guidelines on PE for older adults with sarcopenia [19, 50], MBIs provided by the Oxford Mindfulness Centre [51] and Bangor University [52]. After the initail version of the MBPE program, a panel of experts including nurses, mindfulness therapist, researchers in gerontology, and geriatrician validated the protocol via a two-round Delphi process (unpublished yet). The comments and suggestions from the older adults with sarcopenia were collected to refine the MBPE protocol in this proposed study. The study will be conducted in a hybrid mode, combination of at CHCC and at home [53, 54].

Conceptual framework of the MBPE program

Two theories, the PRIME theory of motivation (S1 Fig) and the mindful coping model (S2 Fig), was adopted to establish the conceptual framework of the MBPE program (Fig 3). Based on the mindful coping model, the mindfulness component in the MBPE program can enhance the motivation for PE by enhancing three essential elements of human motivation in the PRIME theory of motivation: focusing on the present moment, accepting of negative feelings (Self-awareness and Motives), and evoking positive feelings (Motives), which eventually maximize the benefits of PE and improve the physical health of the participants. In addition, the mindful coping model indicates that the mindfulness practice can improve the psychological health of older adults with sarcopenia.

Intervention description

1. The MBPE intervention in the IG

The MBPE intervention aims to help participants learn mindfulness and maintain the state of mindful during PE to improve their experiences of PE and motivation to perform PE [27, 38]. Each session will last for approximately 60 min and have a concrete theme, learning objectives and corresponding activities, including a 5–10-min introduction, 20-min MBI, 30-min PE and 5–10-min sharing and discussion [49, 51, 52]; details are provided in Table 2. The contents and activities of the MBI components will be adapted to the theme of each session, whereas the PE movements will be the same throughout the program but with increased intensity every two weeks until a moderate intensity (measured using the Borg scale) is achieved [50]. The MBPE intervention will be conducted twice a week for 12 weeks [19]. The content of week 8 will be repeated in weeks 9–12 to enhance the benefits of MBPE and help the participants incorporate MBPE into their daily lives, given that they are expected to be able to learn the MBI within 8 weeks [54]. To better combine the MBI and PE components, tips on remaining mindful during PE will be given to the participants.

Table 2. Themes, mindfulness and PE components in the MBPE intervention.
Week Theme of each session Objectives MBI component (20 min) PE component (40 min)
1 Introduction to MBPE Help participants to understand mindfulness, MBPE and key points of keeping mindful 1) Mini lectures on mindfulness, MBPE and key points of remaining mindful during PE
2) Initial experience of mindfulness (3-min breath meditation)
PE movement
1) Warm up (10 min): mindful torso rotation, mindful shoulder rotation, mindful wrist wrap, mindful knee circles, mindful ankle rotation
2) RE (20 min): mindful lateral hand raises, mindful hip abduction, mindful bicep flexors, mindful straight leg lift, mindful handgrip strength exercise, mindful toes up, mindful heels up
3) Cool down (10 min): mindful bicep stretch, mindful tricep stretch, mindful calf stretch, mindful quadricep stretch, mindful cross-legged twist, mindful back stretch
PE intensity
1) Fairly light (10–11 on Borg scale)
2) 2 sets, 8–10 repeats
2 Paying attention to breath during static and dynamic movements Help participants to understand the characteristics of mindfulness and learn how to pay attention to breath 1) Mini lectures on the key characteristics of mindfulness and the importance of focusing on breath, especially for older people with sarcopenia
2) Mindful practice: 6-min breath meditation
3) Tips on paying attention to breath during PE
PE movement
Same as Week 1
PE intensity
Same as Week 1
3 Paying attention to body sensations during static and dynamic movements Help participants to understand the importance of paying attention to the body and know how to do so 1) Mini lectures on body sensations and appreciation
2) Mindful practice: 10-min body scan
3) Tips on paying attention to body sensations during PE
PE movement
Same as Week 1
PE intensity
1) Somewhat hard (11–12 on Borg scale)
2) 2 sets, 10–12 repeats
4 Working with pain, challenges, and stress Help participants to learn to notice pain, challenges and stress in the body and to observe their physical limitations non-attachedly 1) Mini lecture on pain and stress, especially those that older adults with sarcopenia commonly have in daily life
2) Mindful practice of noticing and observing pain, challenges and stress: 10-min seated meditation
3) Tips on noticing physical pain, limitations, stress or challenges during PE
PE movement
Same as Week 1
PE intensity
Same as Week 3
5 Working with thoughts during stillness and PE Help participants to understand the relationship between thoughts and facts and learn to notice thoughts non-judgementally 1) Mini lecture on the conditioned mind: using some common thoughts of older adults with sarcopenia to elaborate on the topic
2) Awareness of our thoughts: 7-min sitting meditation
3) Tips on noticing and dealing with thoughts during PE
PE movement
Same as Week 1
PE intensity
1) Hard (12–14 on Borg scale)
2) 3 sets, 8–15 repeats
6 Understanding habitual thinking patterns during life and PE Help participants to understand that behaviour, thoughts and feelings are interwoven, and learn to notice the tendency to label things during PE 1) Mini lectures on becoming unstuck and having a flexible mind: using common negative feelings of older adults with sarcopenia to show how these negative feelings stick in the mind, behaviour, etc.
2) Mindful practice: 7-min sitting meditation
3) Tips on observing the tendency to label things during PE
PE movement
Same as Week 1
PE intensity
Same as Week 5
7 Self-compassion during life and PE Help participants to understand self-compassion, how to improve self-compassion and show more appreciation towards PE and life 1) Mini lectures on compassion vs criticism and nourishing vs depleting activities
2) Mindful practice: 7-min loving meditation
3) Tips on self-compassion during PE
PE movement
Same as Week 1
PE intensity
Same as Week 5
8 Mindfulness-based PE and mindfulness in life Help participants to learn to integrate mindfulness and MBPE into daily life and to view things from a beginner’s perspective 1) Mini lecture on incorporating mindfulness and mindfulness-based PE into daily life: what informal mindfulness activities we can do in daily life; when, where and how to do formal mindfulness practice, etc.
2) Mini lecture on keeping a beginner’s mindset: its importance and how to re-view the things that we ignore or take for granted
3) Mindful practice: 7-min sitting meditation with life nourishment
PE movement
Same as Week 1
PE intensity
Same as Week 5

MBI, Mindfulness-Based Intervention; MBPE, Mindfulness-Based Physical Exercise; PE, Physical Exercise.

To facilitate the participants’ learning, the face-to-face sessions will be provided in the first four weeks under the supervision of a qualified mindfulness therapist and a qualified sports coach in small groups of 6–10 participants to ensure adequate supervision at the CHCC [55]. Then, the intervention sessions will gradually transition to hybrid mode during weeks 5–12. Specifically, the participants will attend the face-to-face sessions once a week in weeks 5–8 and once every two weeks in weeks 9–12. To achieve a session frequency of twice a week, in addition to the sessions at the CHCC, the participants will perform the interventions at home using videos and templates containing the MBIs and PE components of our MBPE intervention.

2. Health education in the CG

The aim of the CG will be to avoid the influence of socialisation and interaction with others on the participants’ motivation to perform PE and thus isolate the effectiveness of the MBPE program. Thus, health education consisting of discussions provided by a registered nurse will be conducted. The number of sessions, duration, frequency, group size and delivery modality of the CG will be similar to those of the IG. The topics of this health education will be the prevention and management of common diseases among older adults, such as hypertension and diabetes, and will not include MBI or PE.

Primary outcomes and measures

The primary outcomes of this pilot RCT will be the feasibility and acceptability of the MBPE intervention.

1. Feasibility of the MBPE intervention

Feasibility will be evaluated using the time spent recruiting participants, the eligibility rate (number of eligible participants / number of screened participants) and the recruitment rate (number of participants recruited / number of eligible participants).

2. Acceptability of the MBPE program

Acceptability will be evaluated using the prospective acceptability, the concurrent acceptability and the retrospective acceptability [56]. Prospective acceptability will be measured as the recruitment rate and the reasons for which older adults did not get involved in the program[56]. Concurrent acceptability will be assessed using the attendance rate (sessions attended by the participants / all sessions), completion rate (sessions in which participants were actually involved and at least 80% completed / all attended sessions), attrition rate (number of participants dropping out / total number of participants) and the reasons for discontinuing [56]. Attrition will be considered if the completion rate is less than 80%. To have a depth exploration of the participants’ experience and avoid leaking privacy, individual interviews will be used to measure the retrospective acceptability, the detailed guideline in Table 3. The individual interviews will be conducted by two researchers who both have experience in individual interviewing and are familiar with sarcopenia and mindfulness. Purposive sampling will be used, and the sample size will depend on the data duration. Reflective journals written by the interviewers will be used to avoid bias and ensure the transparency of the research process [57]. With the participants’ consent, the individual interviews will be carried out face-to-face and audio recorded.

Table 3. Guide to individual interviewing of participants in intervention group.
Number Questions
Q1 Generally, what do you think of this intervention?
Prompts:
-Can you share your feelings about this intervention?
-What impact do you think this intervention will have on your life?
Q2 What do you think of the content of this intervention?
Prompts:
-Which is your favourite part of this intervention? Why?
-Which part do you dislike? Why?
Q3 What do you think of the frequency, duration and delivery mode of this intervention?
Prompts:
-What duration of the intervention do you think is suitable for you? Why?
-What frequency of the intervention do you think is suitable for you? Why?
-What do you think of the delivery mode of this intervention?
Q4 How about your motivation to exercise?
Prompts:
Has it increased? How and why?
Are you feeling confident about doing physical exercise?
Q5 What recommendations do you have for this intervention?
Prompts:
-What do you think should be added? Why?
-What do you think should be revised or deleted? Why?

Secondary outcome measures

1. The symptoms of sarcopenia

Following the AWGS 2019 [43], the symptoms of sarcopenia include low muscle mass, low handgrip strength and low 5-time chair-stand test scores. Handgrip strength is the primary efficacy outcome as it is the first-line indicator to diagnose sarcopenia [43]. Muscle mass will be assessed via calculating SMI, appendicular skeletal muscle mass, fat-free body weight and total skeletal muscle mass by bioelectrical impedance analysis (Inbody 270, Korea) [58]. Handgrip strength will be measured by a Jamar dynamometer (Jamar, 563213, USA) as recommended by the American Society of Hand Therapists [59]. The maximum value of dominant hand grip strength will be utilised as the result. In the 5-time chair-stand test, the participants will be invited to stand and sit from a chair (approximately 43 cm high) five times and the time taken to complete this exercise will be recorded. Two tests will be conducted with a 1-min interval and the mean of the test results will be taken.

2. Motivation to exercise

The motivation to exercise will be evaluated using the Chinese version of the Behavioural Regulation in Exercise Questionnaire-2 (C-BREQ-2), which has been tested in Chinese people and shown good consistency (Cronbach’s α: 0.72–0.83) [60]. The C-BREQ-2 is a self-report measure with 18 items, divided into five domains: amotivation, external regulation, introjected regulation, identified regulation and intrinsic regulation.

3. Depressive symptoms

Depressive symptoms will be measured with the Chinese version of the short-form Geriatric Depression Scale (GDS-15). The GDS-15 has shown acceptable reliability and validity (Cronbach’s α: 0.793, test–re-test reliability: 0.728) in Chinese older adults [61]. Depressive symptoms are classified based on the score as follows: 0–4: normal; 5–8: mild depression; 9–11: moderate depression; 12–15: severe depression [62].

4. Psychological well-being

Psychological well-being will be measured with the Chinese version of Raff’s Psychological Well-being Scale, as adapted by Tan [63]. The Cronbach’s α of this version is 0.89 and the test–re-test reliability is 0.90.

5. Physical activity level

Physical activity level will be evaluated using the Chinese Version of the Physical Activity Scale for the Elderly (PASE-C) [64]. The PASE-C has shown good reliability (intraclass correlation coefficient: 0.81) [65] and validity (fair to moderate association with energy expenditure, walking steps and handgrip strength) [66].

6. Mindfulness level

The mindfulness level of the participants will be assessed using the short Chinese version of the Five Facet Mindfulness Questionnaire (FFMQ-15-C). The FFMQ-15-C is a self-rated scale developed by Zhu et al. [67] with acceptable reliability (Cronbach’s α of all five facets: ≥ 0.73). It includes 15 items rated on a 5-point Likert scale, ranging from 1 = ‘never or very rarely true’ to 5 = ‘very often or always true’ to evaluate the five facets of mindfulness: observing, describing, acting with awareness, non-judging and non-reacting.

7. Quality of life

Quality of life will be measured with a questionnaire targeted at sarcopenic older people, namely Sarcopenia and Quality of Life (SarQoL®), which was first developed by Beaudart in 2015 and has been translated into more than 30 languages [68]. The Chinese version of SarQoL® was introduced and validated by Li with excellent consistency (Cronbach’s α: 0.867) and test–re-test reliability (0.997) [69].

In addition to socio-demographic information, the outcomes will be evaluated at baseline and immediately after the intervention. The assessors will learn and practice the questionnaires or outcome measurements until the re-test reliability is more than 90% before assessment.

Data management

To protect the security and confidentiality of the data, the personal information (e.g., name, address, contacts) of the participants will be stored on an encrypted hard disk and only the researchers will have access to it. The paper questionnaires will be locked in the researchers’ office. All information collected will only be used for this study and will not be disclosed. A codebook containing information on each variable will be created before the data entry step. All the data will be coded and entered by two researchers independently. Only the core members (MLL, PPKK and JYWL) of this research team can access the data.

Data monitoring

Throughout the study, the corresponding author (PPKK) will monitor recruitment, intervention and retention with the research team (MLL, JYWL and ZYZ). The research team will meet regularly to plan and evaluate the daily activities of this study. The procedure of recruitment, the intervention content, the preparation of assessment, training of research assistants, data management and data analysis will be prepared and monitored by the research team. Besides, the intervention fidelity will be checked by two research assistants.

Statistical analysis

1. Quantitative data analysis

IBM SPSS 23.0 will be used to statistically analyse the data. For continuous variables, the Shapiro–Wilk test will used to evaluate normality. Mean and standard deviation (SD) will used to describe normally distributed data, especially the outcomes to provide information for calculation of standards effect sizes of the subsequent RCT; otherwise, median, interquartile range (P25, P75) and range (minimum, maximum) will be used.

For continuous variables, an independent-samples t test will be used if the data are normally distributed; otherwise, the Mann–Whitney U test will be used. Chi-square or Fisher’s tests will be used for categorical data. Feasibility and acceptability will be presented in terms of rate or absolute number based on the nature of the data. The generalised estimating equation model will be used to analyse the preliminary effects of this study. The standardised mean difference with corresponding 95% confidence intervals will be presented to describe the mean differences of both primary and secondary outcomes between the intervention group and the control group [70]. All data analyses will be conducted with two-tailed tests with a significance level of p < 0.05. Both per-protocol (PP) and intention-to-treat analysis will be conducted. The attention rate >80% will be included in the PP analysis.

2. Qualitative data analysis

Braun and Clarke’s thematic approach will be used to analyse the qualitative data inductively [71]. Two researchers will listen to the recordings repeatedly to prepare a transcript, perform coding and sort the codes into themes. A final code framework will be formed by refining and defining the themes repeatedly through group discussion among the two researchers and a third researcher. The data will be continuously analysed until no new themes emerge. The Lincoln and Guba criteria [72] will be followed to improve the rigor of the qualitative analysis.

Ethics and dissemination

Ethical approval for this study has been obtained from the Institutional Review Board of The Hong Kong Polytechnic University (reference number: HSEARS20221117005). This trial has been registered with ClinicalTrials.gov Protocol Registration (ID: NCT05982067). The principles of the Declaration of Helsinki will be followed: autonomy, non-maleficence and beneficence, and confidentiality.

After being fully informed about this study, prospective participants will independently decide whether to participate, and written informed consent will be obtained from those willing to join. They will be free to choose to withdraw from the study at any time. Their right to access health services at the CHCCs will not be influenced. This study is very unlikely to cause harm to the participants, as the MBPE program is evidence- and theory-based and has been evaluated by experts and older people with sarcopenia. All information collected will be used only for this study and will not be disclosed. When disseminating the MBPE program, only research results that do not contain any private information will be presented.

Adverse events

For the potential risk, the participants may experience mild muscle soreness during the first 2–3 sessions, which is normal for inactive people starting PE. We will try our best to minimise the occurrence of muscle soreness by fully considering the characteristics of our participants, such as gradually increasing the intensity from low to moderate and separating adjacent sessions by two days to let the participants fully recover. However, if muscle soreness or other discomfort does occur, a professional rehabilitation therapist will be referred for further assessment.

Patient and public involvement

During the development of the MBPE program, older adults with sarcopenia were invited to give comments and suggestions on the initial MBPE intervention protocol. The evaluation of participants with lived experience helped us to review the MBPE program from their perspectives and further modify the protocol to make it more practical and suitable in real life and more tailored to the target population. Additionally, the participants’ opinions on the MBPE program will be collected during and after the pilot RCT to further revise the program in readiness for a full RCT.

Discussion

Sarcopenia is prevalent in older adults and increases the risks of numerous adverse events [58]. Although PE is the key treatment for sarcopenia, adherence to PE is low in older people with sarcopenia, undermining the benefits. This study is the first study to adopt an MBPE intervention, combining an MBI and conventional PE, aiming to maximise the effects of PE via enhancing motivation and adherence.

Although PE is the key strategy to treat sarcopenia, older adults with sarcopenia are more likely to have negative thoughts and feelings towards PE, such as feeling fatigue or discomfort while doing exercise [73], feeling sad or hopeless when they think they are unable to do the intended PE, and feeling being too old or too dangerous to perform any PE [20]. These negative feelings or experiences greatly diminish their motivation to participate in or maintain PE interventions and their psychological well-being. However, few studies have considered these negative feelings of older adults with sarcopenia in their PE interventions. Based on the PRIME theory of motivation and the mindful coping model [24, 35], MBI can be combined with PE to improve the motivation to perform PE through several means: addressing motives, focusing on the present moment, accepting negative feelings and evoking positive feelings. The ability to be more aware of thoughts, emotions and physical sensations during the PE, can be powerfully for helping participants to disengage from their physically inactive lifestyles or negative feelings towards PE and have positive feelings and experiences [74]. More importantly, MBI can impact the response process of the participants’ brain and enable them to change their behaviour from the inside, which may be much superior to behaviour change than some techniques from the outside, such as reminder, goals setting, problem solving, which are like to “push” the participants to change [75].

Considering the limited studies using MBPE in older people with sarcopenia [39, 40], our program will provide evidence on the feasibility, acceptability and preliminary effects of MBPE interventions in this field. For health professionals, the study will provide a potentially effective way to improve motivation and adherence among recipients of PE interventions for sarcopenia. For older people with sarcopenia, this study has the potential to improve their holistic well-being, both physically (in terms of symptoms of sarcopenia) and psychologically.

Strength and limitation

This study will have several strengths. First, the MBPE intervention protocol has been reviewed by an international panel of experts to maximise the rationality, scientific basis and safety of the program. Second, the evaluation of older adults with lived experience of sarcopenia during program development helped us to tailor the MBPE intervention to the participants and real-life practicalities. Third, the individual interviews after the intervention will allow us to further improve the program in readiness for a full RCT via fully considering the participants’ perspectives.

Despite its strengths, this pilot study will have several limitations. First, due to practical limitations (e.g., time, money), the long-term effects of the MBPE intervention will not be explored. Second, the nature of a pilot RCT could undermine the power of statistical tests of the effectiveness of the MBPE program. Thus, a full RCT will be required to accurately test the effectiveness of the MBPE program in future. Finally, as this study will target community-dwelling older people with sarcopenia, the effectiveness of the MBPE program for older adults with sarcopenia in other settings (e.g., nursing homes, hospitals) will remain to be explored.

Supporting information

S1 Appendix. The SPIRIT Checklist of the study.

(DOCX)

pone.0302235.s001.docx (38.1KB, docx)
S2 Appendix. The informed consent form.

(DOCX)

pone.0302235.s002.docx (15.4KB, docx)
S3 Appendix. The original study protocol approved by ethics committee.

(PDF)

pone.0302235.s003.pdf (835.4KB, pdf)
S1 Fig. The PRIME theory of motivation.

(TIF)

pone.0302235.s004.tif (304.1KB, tif)
S2 Fig. The mindful coping model.

(TIF)

pone.0302235.s005.tif (85.8KB, tif)

Data Availability

No datasets were generated or analysed during the current study. All relevant data from this study will be made available upon study completion.

Funding Statement

The author(s) received no specific funding for this work.

References

  • 1.Cruz-Jentoft AJ, Sayer AA. Sarcopenia. Lancet. 2019;393(10191):2636–46. doi: 10.1016/S0140-6736(19)31138-9 [DOI] [PubMed] [Google Scholar]
  • 2.Cao L, Morley JE. Sarcopenia Is Recognized as an Independent Condition by an International Classification of Disease, Tenth Revision, Clinical Modification (ICD-10-CM) Code. Journal of the American Medical Directors Association. 2016;17(8):675–7. doi: 10.1016/j.jamda.2016.06.001 [DOI] [PubMed] [Google Scholar]
  • 3.World Health Organization. Ageing and health 2021 [cited 2021 11]. https://www.who.int/news-room/fact-sheets/detail/ageing-and-health.
  • 4.Mayhew AJ, Amog K, Phillips S, Parise G, McNicholas PD, de Souza RJ, et al. The prevalence of sarcopenia in community-dwelling older adults, an exploration of differences between studies and within definitions: a systematic review and meta-analyses. Age Ageing. 2019;48(1):48–56. doi: 10.1093/ageing/afy106 [DOI] [PubMed] [Google Scholar]
  • 5.Beaudart C, Zaaria M, Pasleau F, Reginster JY, Bruyère O. Health Outcomes of Sarcopenia: A Systematic Review and Meta-Analysis. PLoS One. 2017;12(1):e0169548. doi: 10.1371/journal.pone.0169548 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Yang M, Liu Y, Zuo Y, Tang H. Sarcopenia for predicting falls and hospitalization in community-dwelling older adults: EWGSOP versus EWGSOP2. Scientific reports. 2019;9(1):17636. doi: 10.1038/s41598-019-53522-6 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Nakamura K, Yoshida D, Honda T, Hata J, Shibata M, Hirakawa Y, et al. Prevalence and Mortality of Sarcopenia in a Community-dwelling Older Japanese Population: The Hisayama Study. Journal of epidemiology. 2021;31(5):320–7. doi: 10.2188/jea.JE20190289 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Chang KV, Hsu TH, Wu WT, Huang KC, Han DS. Is sarcopenia associated with depression? A systematic review and meta-analysis of observational studies. Age Ageing. 2017;46(5):738–46. doi: 10.1093/ageing/afx094 [DOI] [PubMed] [Google Scholar]
  • 9.Bruyère O, Beaudart C, Ethgen O, Reginster JY, Locquet M. The health economics burden of sarcopenia: a systematic review. Maturitas. 2019;119:61–9. doi: 10.1016/j.maturitas.2018.11.003 [DOI] [PubMed] [Google Scholar]
  • 10.Kwak JY, Kwon KS. Pharmacological Interventions for Treatment of Sarcopenia: Current Status of Drug Development for Sarcopenia. ANNALS OF GERIATRIC MEDICINE AND RESEARCH. 2019;23(3):98–104. doi: 10.4235/agmr.19.0028 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Wu PY, Huang KS, Chen KM, Chou CP, Tu YK. Exercise, Nutrition, and Combined Exercise and Nutrition in Older Adults with Sarcopenia: A Systematic Review and Network Meta-analysis. Maturitas. 2021;145:38–48. doi: 10.1016/j.maturitas.2020.12.009 [DOI] [PubMed] [Google Scholar]
  • 12.Bao W, Sun Y, Zhang T, Zou L, Wu X, Wang D, et al. Exercise Programs for Muscle Mass, Muscle Strength and Physical Performance in Older Adults with Sarcopenia: A Systematic Review and Meta-Analysis. Aging Dis. 2020;11(4):863–73. doi: 10.14336/AD.2019.1012 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.de Mello RGB, Dalla Corte RR, Gioscia J, Moriguchi EH. Effects of Physical Exercise Programs on Sarcopenia Management, Dynapenia, and Physical Performance in the Elderly: A Systematic Review of Randomized Clinical Trials. J Aging Res. 2019;2019:1959486. doi: 10.1155/2019/1959486 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Lozano-Montoya I, Correa-Perez A, Abraha I, Soiza RL, Cherubini A, O’Mahony D, et al. Nonpharmacological interventions to treat physical frailty and sarcopenia in older patients: a systematic overview—the SENATOR Project ONTOP Series. Clinical Interventions in Aging. 2017;12:721–40. doi: 10.2147/CIA.S132496 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Yoshimura Y, Wakabayashi H, Yamada M, Kim H, Harada A, Arai H. Interventions for Treating Sarcopenia: A Systematic Review and Meta-Analysis of Randomized Controlled Studies. J Am Med Dir Assoc. 2017;18(6):553.e1-.e16. doi: 10.1016/j.jamda.2017.03.019 [DOI] [PubMed] [Google Scholar]
  • 16.Hurst C, Robinson SM, Witham MD, Dodds RM, Granic A, Buckland C, et al. Resistance exercise as a treatment for sarcopenia: prescription and delivery. Age and ageing. 2022;51(2):afac003. doi: 10.1093/ageing/afac003 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Thiebaud RS, Funk MD, Abe T. Home-based resistance training for older adults: A systematic review. Geriatrics & Gerontology International. 2014;14(4):750–7. doi: 10.1111/ggi.12326 [DOI] [PubMed] [Google Scholar]
  • 18.Mañas A, Gómez-Redondo P, Valenzuela PL, Morales JS, Lucía A, Ara I. Unsupervised home-based resistance training for community-dwelling older adults: A systematic review and meta-analysis of randomized controlled trials. Ageing Res Rev. 2021;69:101368. doi: 10.1016/j.arr.2021.101368 [DOI] [PubMed] [Google Scholar]
  • 19.Izquierdo M, Merchant R, Morley J, Anker S, Aprahamian I, Arai H, et al. International exercise recommendations in older adults (ICFSR): expert consensus guidelines. The journal of nutrition, health & aging. 2021;25(7):824–53. doi: 10.1007/s12603-021-1665-8 [DOI] [PubMed] [Google Scholar]
  • 20.Herrema AL, Westerman MJ, van Dongen EJ, Kudla U, Veltkamp M. Combined protein-rich diet with resistance exercise intervention to counteract sarcopenia: A qualitative study on drivers and barriers of compliance. Journal of aging and physical activity. 2018;26(1):106–13. doi: 10.1123/japa.2017-0126 [DOI] [PubMed] [Google Scholar]
  • 21.Dismore L, Hurst C, Sayer AA, Stevenson E, Aspray T, Granic A. Study of the older adults’ motivators and barriers engaging in a nutrition and resistance exercise intervention for sarcopenia: an embedded qualitative project in the MIlkMAN Pilot study. Gerontology and Geriatric Medicine. 2020;6:2333721420920398. doi: 10.1177/2333721420920398 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Kwon YN, Yoon SS. Sarcopenia: Neurological Point of View. jbm. 2017;24(2):83–9. doi: 10.11005/jbm.2017.24.2.83 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Billot M, Calvani R, Urtamo A, Sánchez-Sánchez JL, Ciccolari-Micaldi C, Chang M, et al. Preserving Mobility in Older Adults with Physical Frailty and Sarcopenia: Opportunities, Challenges, and Recommendations for Physical Activity Interventions. Clinical interventions in aging. 2020;15:1675–90. doi: 10.2147/CIA.S253535 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.West R. Towards a comprehensive theory of addiction. Drugs and Alcohol Today. 2006;6(1):28–32. [Google Scholar]
  • 25.Chapman P, van Loon E, Trawley S, Crundall D, editors. A comparison of drivers’ eye movements in filmed and simulated dangerous driving situations. Behavioural research in road safety, 2007: Seventeenth seminar; 2007. [Google Scholar]
  • 26.Ahmad MH, Shahar S, Teng NI, Manaf ZA, Sakian NI, Omar B. Applying theory of planned behavior to predict exercise maintenance in sarcopenic elderly. Clin Interv Aging. 2014;9:1551–61. doi: 10.2147/CIA.S60462 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.West R, Michie S. A brief introduction to the COM-B Model of behaviour and the PRIME Theory of motivation. Qeios. 2020. [Google Scholar]
  • 28.Li Z, Tong X, Ma Y, Bao T, Yue J. Prevalence of depression in patients with sarcopenia and correlation between the two diseases: systematic review and meta-analysis. Journal of cachexia, sarcopenia and muscle. 2022. doi: 10.1002/jcsm.12908 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Zimmermann FF, Burrell B, Jordan J. The acceptability and potential benefits of mindfulness-based interventions in improving psychological well-being for adults with advanced cancer: A systematic review. Complementary therapies in clinical practice. 2018;30:68–78. doi: 10.1016/j.ctcp.2017.12.014 [DOI] [PubMed] [Google Scholar]
  • 30.Reangsing C, Rittiwong T, Schneider JK. Effects of mindfulness meditation interventions on depression in older adults: A meta-analysis. Aging & Mental Health. 2021;25(7):1181–90. doi: 10.1080/13607863.2020.1793901 [DOI] [PubMed] [Google Scholar]
  • 31.Goldberg SB, Tucker RP, Greene PA, Davidson RJ, Wampold BE, Kearney DJ, et al. Mindfulness-based interventions for psychiatric disorders: A systematic review and meta-analysis. Clin Psychol Rev. 2018;59:52–60. doi: 10.1016/j.cpr.2017.10.011 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Ruffault A, Bernier M, Juge N, Fournier JF. Mindfulness May Moderate the Relationship Between Intrinsic Motivation and Physical Activity: A Cross-Sectional Study. Mindfulness. 2016;7(2):445–52. doi: 10.1007/s12671-015-0467-7 [DOI] [Google Scholar]
  • 33.Hardison ME, Roll SC. Mindfulness Interventions in Physical Rehabilitation: A Scoping Review. American Journal of Occupational Therapy. 2016;70(3). doi: 10.5014/ajot.2016.018069 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Tsafou KE, Lacroix JP, van Ee R, Vinkers CD, De Ridder DT. The relation of trait and state mindfulness with satisfaction and physical activity: A cross-sectional study in 305 Dutch participants. J Health Psychol. 2017;22(10):1221–32. doi: 10.1177/1359105315624748 [DOI] [PubMed] [Google Scholar]
  • 35.Schneider J, Malinowski P, Watson PM, Lattimore P. The role of mindfulness in physical activity: a systematic review. Obesity Reviews. 2019;20(3):448–63. doi: 10.1111/obr.12795 [DOI] [PubMed] [Google Scholar]
  • 36.Robin N, Toussaint L, Sinnapah S, Hue O, Coudevylle GR. Beneficial Influence of Mindfulness Training Promoted by Text Messages on Self-Reported Aerobic Physical Activity in Older Adults: A Randomized Controlled Study. Journal of Aging and Physical Activity. 2020;28(3):406–14. doi: 10.1123/japa.2019-0002 [DOI] [PubMed] [Google Scholar]
  • 37.Yang CH, Conroy DE. Feasibility of an Outdoor Mindful Walking Program for Reducing Negative Affect in Older Adults. J Aging Phys Act. 2018:1–10. doi: 10.1123/japa.2017-0390 [DOI] [PubMed] [Google Scholar]
  • 38.Garland EL, Gaylord SA, Fredrickson BL. Positive reappraisal mediates the stress-reductive effects of mindfulness: An upward spiral process. Mindfulness. 2011;2(1):59–67. [Google Scholar]
  • 39.Pandya SP. Yoga education program for older women diagnosed with sarcopenia: A multicity 10-year follow-up experiment. J Women Aging. 2019;31(5):446–69. doi: 10.1080/08952841.2018.1510245 [DOI] [PubMed] [Google Scholar]
  • 40.Zhu YQ, Peng N, Zhou M, Liu P-p, Qi X-l, Wang N, et al. Tai Chi and whole-body vibrating therapy in sarcopenic men in advanced old age: a clinical randomized controlled trial. European journal of ageing. 2019;16(3):273–82. doi: 10.1007/s10433-019-00498-x [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41.Chan AW, Tetzlaff JM, Altman DG, Laupacis A, Gøtzsche PC, Krleža-Jerić K, et al. SPIRIT 2013 statement: defining standard protocol items for clinical trials. Ann Intern Med. 2013;158(3):200–7. doi: 10.7326/0003-4819-158-3-201302050-00583 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42.Eldridge SM, Chan CL, Campbell MJ, Bond CM, Hopewell S, Thabane L, et al. CONSORT 2010 statement: extension to randomised pilot and feasibility trials. BMJ. 2016;355:i5239. doi: 10.1136/bmj.i5239 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 43.Chen L-K, Woo J, Assantachai P, Auyeung T-W, Chou M-Y, Iijima K, et al. Asian Working Group for Sarcopenia: 2019 Consensus Update on Sarcopenia Diagnosis and Treatment. Journal of the American Medical Directors Association. 2020;21(3). doi: 10.1016/j.jamda.2019.12.012 [DOI] [PubMed] [Google Scholar]
  • 44.World Health Organization. Physical activity 2022 [cited 2022 10 Spetember]. https://www.who.int/news-room/fact-sheets/detail/physical-activity.
  • 45.Greenberg J, Popok PJ, Lin A, Kulich RJ, James P, Macklin EA, et al. A Mind-Body Physical Activity Program for Chronic Pain With or Without a Digital Monitoring Device: Proof-of-Concept Feasibility Randomized Controlled Trial. JMIR Form Res. 2020;4(6):e18703. doi: 10.2196/18703 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 46.Whitehead AL, Julious SA, Cooper CL, Campbell MJ. Estimating the sample size for a pilot randomised trial to minimise the overall trial sample size for the external pilot and main trial for a continuous outcome variable. Statistical methods in medical research. 2016;25(3):1057–73. doi: 10.1177/0962280215588241 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 47.Cramer JT, Cruz-Jentoft AJ, Landi F, Hickson M, Zamboni M, Pereira SL, et al. Impacts of High-Protein Oral Nutritional Supplements Among Malnourished Men and Women with Sarcopenia: A Multicenter, Randomized, Double-Blinded, Controlled Trial. Journal of the American Medical Directors Association. 2016;17(11):1044–55. doi: 10.1016/j.jamda.2016.08.009 [DOI] [PubMed] [Google Scholar]
  • 48.Craig P, Dieppe P, Macintyre S, Michie S, Nazareth I, Petticrew M. Developing and evaluating complex interventions: the new Medical Research Council guidance. BMJ. 2008;337:a1655. doi: 10.1136/bmj.a1655 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 49.Li ML, Kor PP, Sui YF, Liu JY. Health maintenance through home-based interventions for community-dwelling older people with sarcopenia during and after the COVID-19 pandemic: A systematic review and meta-analysis. Exp Gerontol. 2023;174:112128. doi: 10.1016/j.exger.2023.112128 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 50.Beckwée D, Delaere A, Aelbrecht S, Baert V, Beaudart C, Bruyere O, et al. Exercise Interventions for the Prevention and Treatment of Sarcopenia: A Systematic Umbrella Review. J Nutr Health Aging. 2019;23(6):494–502. doi: 10.1007/s12603-019-1196-8 [DOI] [PubMed] [Google Scholar]
  • 51.Oxford Mindfulness Foundation. Mindfulness: Finding Peace in a Frantic World 2007 [cited 2022]. https://www.oxfordmindfulness.org/learn-mindfulness/course-types/introducing-mindfulness/.
  • 52.Bangor University. The 8-week Mindfulness course 2022 [cited 2022 1 September]. https://www.bangor.ac.uk/mindfulness/books.php.en?menu=26&catid=10013&subid=0.
  • 53.Purdie DR, Federman M, Chin A, Winston D, Bursch B, Olmstead R, et al. Hybrid Delivery of Mindfulness Meditation and Perceived Stress in Pediatric Resident Physicians: A Randomized Clinical Trial of In-Person and Digital Mindfulness Meditation. J Clin Psychol Med Settings. 2022. doi: 10.1007/s10880-022-09896-3 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 54.Kor PPK, Li ML, Kwok DKS, Leung AYM, Lai DLL, Liu JYW. Evaluating the effectiveness of a 6-week hybrid mindfulness-based intervention in reducing the stress among caregivers of patients with dementia during COVID-19 pandemic: protocol of a randomized controlled trial. BMC psychology. 2022;10(1):1–13. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 55.Zhu L-Y, Chan R, Kwok T, Cheng KC-C, Ha A, Woo J. Effects of exercise and nutrition supplementation in community-dwelling older Chinese people with sarcopenia: a randomized controlled trial. Age and ageing. 2019;48(2):220–8. doi: 10.1093/ageing/afy179 [DOI] [PubMed] [Google Scholar]
  • 56.Sekhon M, Cartwright M, Francis JJ. Acceptability of healthcare interventions: an overview of reviews and development of a theoretical framework. BMC Health Services Research. 2017;17(1):88. doi: 10.1186/s12913-017-2031-8 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 57.Ortlipp M. Keeping and using reflective journals in the qualitative research process. The qualitative report. 2008;13(4):695–705. [Google Scholar]
  • 58.Böhm A, Heitmann BL. The use of bioelectrical impedance analysis for body composition in epidemiological studies. Eur J Clin Nutr. 2013;67 Suppl 1:S79–85. doi: 10.1038/ejcn.2012.168 [DOI] [PubMed] [Google Scholar]
  • 59.Fess EE. American society of hand therapists. The Journal of Hand Surgery. 1983;8(5):625–7. [Google Scholar]
  • 60.Liu JD, Chung P-K, Zhang C-Q, Si G. Chinese-translated Behavioral Regulation in Exercise Questionnaire-2: evidence from university students in the Mainland and Hong Kong of China. Journal of Sport and Health Science. 2015;4(3):228–34. [Google Scholar]
  • 61.Dan T. Application of Short Form Geriatric Depression Scale (GDS-15) In Chinese Elderly. Application of Short Form Geriatric Depression Scale (GDS-15) In Chinese Elderly. 2013;21:402–5. [Google Scholar]
  • 62.LIU S. The relationship between frailty and depression in elderly hospitalized patients: Peking Union Medical College; 2019. [Google Scholar]
  • 63.TAN S. The longitudinal relationship between test stress and psychological well-being in adolescents: the mediating role of self-esteem: Shaanxi Normal University; 2016. [Google Scholar]
  • 64.Washburn RA, Smith KW, Jette AM, Janney CA. The Physical Activity Scale for the Elderly (PASE): development and evaluation. J Clin Epidemiol. 1993;46(2):153–62. doi: 10.1016/0895-4356(93)90053-4 [DOI] [PubMed] [Google Scholar]
  • 65.Ngai SP, Cheung RT, Lam PL, Chiu JK, Fung EY. Validation and reliability of the Physical Activity Scale for the Elderly in Chinese population. J Rehabil Med. 2012;44(5):462–5. doi: 10.2340/16501977-0953 [DOI] [PubMed] [Google Scholar]
  • 66.Ku P-W, Sun W-J, Chang C-Y, Chen L-J. Reliability and validity of the Chinese version of the physical activity scale for the elderly. Sport & Exercise Research 2013;15(3):309–19. [Google Scholar]
  • 67.Zhu T, Chen C, Chen S. Validation of a Chinese version of the five facet mindfulness questionnaire and development of a short form based on item response theory. Current Psychology. 2021:1–13. [Google Scholar]
  • 68.Sarcopenia and Quality of life. https://sarqol.org/en/sarqol_form.
  • 69.Le X, Wei Y, Hao D, Shan L, Li X, Shi Q, et al. Psychometric properties of the Chinese version of the sarcopenia and quality of life, a quality of life questionnaire specific for sarcopenia. Calcified Tissue International. 2021;109(4):415–22. doi: 10.1007/s00223-021-00859-8 [DOI] [PubMed] [Google Scholar]
  • 70.Cohen J. Statistical power analysis for the behavioral sciences: Routledge; 2013. [Google Scholar]
  • 71.Braun V, Clarke V. One size fits all? What counts as quality practice in (reflexive) thematic analysis? Qualitative research in psychology. 2021;18(3):328–52. [Google Scholar]
  • 72.Schwandt TA, Lincoln YS, Guba EG. Judging interpretations: But is it rigorous? Trustworthiness and authenticity in naturalistic evaluation. New directions for evaluation. 2007;114:11–25. [Google Scholar]
  • 73.Lin T-R, Huang X-Y, Hwu C-M. Exercise Experiences of Older Adults with Diabetes and Sarcopenia: A Phenomenological Study. Clinical Nursing Research. 2021:10547738211039381. doi: 10.1177/10547738211039381 [DOI] [PubMed] [Google Scholar]
  • 74.Yang CH, Conroy DE. Mindfulness and physical activity: a systematic review and hierarchical model of mindfulness. International Journal of Sport and Exercise Psychology. 2020;18(6):794–817. doi: 10.1080/1612197x.2019.1611901 [DOI] [Google Scholar]
  • 75.Chen X, Reed P. The effect of brief mindfulness training on the micro-structure of human free-operant responding: Mindfulness affects stimulus-driven responding. Journal of Behavior Therapy and Experimental Psychiatry. 2023;79. doi: 10.1016/j.jbtep.2022.101821 [DOI] [PubMed] [Google Scholar]

Decision Letter 0

Meryem Merve Ören Çelik

7 Mar 2024

PONE-D-23-43186Feasibility and preliminary effects of a Mindfulness-Based Physical Exercise (MBPE) program for community-dwelling older people with sarcopenia: A protocol for a parallel, two-armed pilot randomised controlled trialPLOS ONE

Dear Dr. Kor, 

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please submit your revised manuscript by Apr 21 2024 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Meryem Merve Ören Çelik

Academic Editor

PLOS ONE

Journal Requirements:

1. When submitting your revision, we need you to address these additional requirements.

Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at 

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and 

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Does the manuscript provide a valid rationale for the proposed study, with clearly identified and justified research questions?

The research question outlined is expected to address a valid academic problem or topic and contribute to the base of knowledge in the field.

Reviewer #1: Yes

Reviewer #2: Yes

**********

2. Is the protocol technically sound and planned in a manner that will lead to a meaningful outcome and allow testing the stated hypotheses?

The manuscript should describe the methods in sufficient detail to prevent undisclosed flexibility in the experimental procedure or analysis pipeline, including sufficient outcome-neutral conditions (e.g. necessary controls, absence of floor or ceiling effects) to test the proposed hypotheses and a statistical power analysis where applicable. As there may be aspects of the methodology and analysis which can only be refined once the work is undertaken, authors should outline potential assumptions and explicitly describe what aspects of the proposed analyses, if any, are exploratory.

Reviewer #1: Yes

Reviewer #2: Yes

**********

3. Is the methodology feasible and described in sufficient detail to allow the work to be replicable?

Descriptions of methods and materials in the protocol should be reported in sufficient detail for another researcher to reproduce all experiments and analyses. The protocol should describe the appropriate controls, sample size calculations, and replication needed to ensure that the data are robust and reproducible.

Reviewer #1: Yes

Reviewer #2: Yes

**********

4. Have the authors described where all data underlying the findings will be made available when the study is complete?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception, at the time of publication. The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above and, if applicable, provide comments about issues authors must address before this protocol can be accepted for publication. You may also include additional comments for the author, including concerns about research or publication ethics.

You may also provide optional suggestions and comments to authors that they might find helpful in planning their study.

(Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: Major Revision Required

This seems a very good protocol for a worthwhile, well designed feasibility trial. However, there are some important points that need to be re-examined.

Page Lines

10 181 This statement needs rephrasing from: “… 25 per group will produce at least a small standardised effect size in a main study [46].” to something like “… 25 per group is likely to provide sufficient information for planning the proposed subsequent main randomised trial with an anticipated standardised effect size of about 0.2 [46].”

18 Primary outcomes and measures: This section needs to stipulate somewhere that a primary outcome is also the estimation of the SD for the main endpoint measure. Feasibility relates to statistical aspects of the future trial as well as practicability. See comments below regarding page 24.

23 Probably best not to conduct statistical significance tests with p-values reported, but merely report (say) the mean difference between the two randomised groups with corresponding 95% confidence intervals.

24 Reference [46] states: “When the outcome is a continuous variable, the sample size calculation requires an accurate estimate of the standard deviation of the outcome measure. A pilot trial can be used to get an estimate of the standard deviation, which could then be used to anticipate what may be observed in the main trial. However, an important consideration is that pilot trials often estimate the standard deviation (SD) parameter imprecisely.”

Thus, the main statistical issue in this feasibility study is to provide information to help ascertain a meaningful standardised effect size. This requires an estimate of the SD for the intended main outcome variable for planning the size of the subsequent randomised Phase III controlled trial. Consequently, the Statistical Analysis section should state this explicitly and thus the eventual results section requires the SD to be reported.

This in turn implies that the principal endpoint for the subsequent trial needs to be identified and clearly stipulated in this Protocol.

Some minor points are listed below:

Page Lines

9 169 ‘CONSORT’ is misspelt

11 203 “Prifysgol” is the Welsh language word for “University” so need not be included here.

24 13 Reporting minimum and maximum values rather than quartiles is likely to be more informative.

24 18-19 I cannot imagine ‘generalised estimating equations; will really be necessary.

Reviewer #2: This protocol is an intervention that addresses a very important problem that concerns public health, gerontology and geriatrics due to its magnitude and significance in the healthy aging process. Sarcopenia is a predictor of dependency, loss of autonomy, increased mortality and higher health care costs. Having scientifically verifiable intervention strategies provides an incentive for their application, even more so by including two factors as important as motivation and adherence that are recognized as problems in maintaining a longer-term program. A randomized controlled pilot trial is a good initial design to continue searching for more viable actions and their effects in the prevention of Sarcopenia.

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: Yes: Elva Dolores Arias Merino.

**********

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

PLoS One. 2024 Apr 18;19(4):e0302235. doi: 10.1371/journal.pone.0302235.r002

Author response to Decision Letter 0


12 Mar 2024

Dear Editor and Reviewers,

Thank you for your time to review our revised manuscript and your valuable comments and suggestions on it. We have made all of the revisions on the paper with careful considerations to your comments and they are described as below. The changes in the manuscript are also highlighted in yellow:

R1(1): 10 181 This statement needs rephrasing from: “…25 per group will produce at least a small standardised effect size in a main study [46].” to something like “…25 per group is likely to provide sufficient information for planning the proposed subsequent main randomised trial with an anticipated standardised effect size of about 0.2 [46].”

Response: We have adopted the suggestions and rephrased the sentence on Page 10, Line 182-184.

R1(2): 18 Primary outcomes and measures: This section needs to stipulate somewhere that a primary outcome is also the estimation of the SD for the main endpoint measure. Feasibility relates to statistical aspects of the future trial as well as practicability. See comments below regarding page 24.

Response: We have supplemented the primary outcome on Page 21, Line 287-288. In this pilot study, the primary outcome is handgrip strength. The standardised mean difference (Conde’s d) with corresponding 95% confidence intervals will be reported to describe the mean differences between the intervention group and the control group (Page 24, Line 367-370).

R1(3): 23 Probably best not to conduct statistical significance tests with p-values reported, but merely report (say) the mean difference between the two randomised groups with corresponding 95% confidence intervals.

Response: We adopted the suggestions and revised the method section on Page 24, Line 367-370:

The standardised mean difference with corresponding 95% confidence intervals will be presented to describe the mean differences of both primary and secondary outcomes between the intervention group and the control group [71]. All data analyses will be conducted with two-tailed tests with a significance level of p < 0.05.

R1(4): 24 Reference [46] states: “When the outcome is a continuous variable, the sample size calculation requires an accurate estimate of the standard deviation of the outcome measure. A pilot trial can be used to get an estimate of the standard deviation, which could then be used to anticipate what may be observed in the main trial. However, an important consideration is that pilot trials often estimate the standard deviation (SD) parameter imprecisely.”

Thus, the main statistical issue in this feasibility study is to provide information to help ascertain a meaningful standardised effect size. This requires an estimate of the SD for the intended main outcome variable for planning the size of the subsequent randomised Phase III controlled trial. Consequently, the Statistical Analysis section should state this explicitly and thus the eventual results section requires the SD to be reported. This in turn implies that the principal endpoint for the subsequent trial needs to be identified and clearly stipulated in this Protocol.

Response: We adopted the suggestions and revised the method section on, Page24, Line 358-361, reporting SD and Page 24, Line 367-370, stating the mean difference (see the above response #R1(3)).

Some minor points are listed below:

Page Lines

R1(5): 9 169 CONSORT is misspelt.

Response: We have revised. Thank you!

R1(6): 11 203 “Prifysgol” is the Welsh language word for “University” so need not be included here.

Response: We have deleted it. Thank you!

R1(7): 24 13 Reporting minimum and maximum values rather than quartiles is likely to be more informative.

Response: We have adopted the suggestions and added the variables of minimum and maximum values on Page 24, Line 360-361.

R1(8): 24 18-19 I cannot imagine “generalised estimating equations” will really be necessary.

Response: After consulting two statisticians, we adopted the GEE analysis because this method accounts for intra-correlated pre-test and post-test measures and accommodates missing data. Besides GEE provide robust results for non-normally distributed continuous data.

Reviewer #2: This protocol is an intervention that addresses a very important problem that concerns public health, gerontology and geriatrics due to its magnitude and significance in the healthy aging process. Sarcopenia is a predictor of dependency, loss of autonomy, increased mortality and higher health care costs. Having scientifically verifiable intervention strategies provides an incentive for their application, even more so by including two factors as important as motivation and adherence that are recognized as problems in maintaining a longer-term program. A randomized controlled pilot trial is a good initial design to continue searching for more viable actions and their effects in the prevention of Sarcopenia.

Response: Thank you for your comments!

Attachment

Submitted filename: Response to Reviewers.docx

pone.0302235.s006.docx (19KB, docx)

Decision Letter 1

Meryem Merve Ören Çelik

1 Apr 2024

Feasibility and preliminary effects of a Mindfulness-Based Physical Exercise (MBPE) program for community-dwelling older people with sarcopenia: A protocol for a parallel, two-armed pilot randomised controlled trial

PONE-D-23-43186R1

Dear Dr. Kor,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice will be generated when your article is formally accepted. Please note, if your institution has a publishing partnership with PLOS and your article meets the relevant criteria, all or part of your publication costs will be covered. Please make sure your user information is up-to-date by logging into Editorial Manager at Editorial Manager® and clicking the ‘Update My Information' link at the top of the page. If you have any questions relating to publication charges, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Meryem Merve Ören Çelik

Academic Editor

PLOS ONE

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Does the manuscript provide a valid rationale for the proposed study, with clearly identified and justified research questions?

The research question outlined is expected to address a valid academic problem or topic and contribute to the base of knowledge in the field.

Reviewer #1: Yes

**********

2. Is the protocol technically sound and planned in a manner that will lead to a meaningful outcome and allow testing the stated hypotheses?

The manuscript should describe the methods in sufficient detail to prevent undisclosed flexibility in the experimental procedure or analysis pipeline, including sufficient outcome-neutral conditions (e.g. necessary controls, absence of floor or ceiling effects) to test the proposed hypotheses and a statistical power analysis where applicable. As there may be aspects of the methodology and analysis which can only be refined once the work is undertaken, authors should outline potential assumptions and explicitly describe what aspects of the proposed analyses, if any, are exploratory.

Reviewer #1: Yes

**********

3. Is the methodology feasible and described in sufficient detail to allow the work to be replicable?

Descriptions of methods and materials in the protocol should be reported in sufficient detail for another researcher to reproduce all experiments and analyses. The protocol should describe the appropriate controls, sample size calculations, and replication needed to ensure that the data are robust and reproducible.

Reviewer #1: Yes

**********

4. Have the authors described where all data underlying the findings will be made available when the study is complete?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception, at the time of publication. The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above and, if applicable, provide comments about issues authors must address before this protocol can be accepted for publication. You may also include additional comments for the author, including concerns about research or publication ethics.

You may also provide optional suggestions and comments to authors that they might find helpful in planning their study.

(Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: Accept

This seems a very good protocol for a worthwhile and well-designed study. The authors have now included the estimation of the standardised effect size for planning an eventually larger Phase III trial as an objective of this study. However, I remain concerned that the statistical analysis plan over complicates the eventual analysis that will be needed. More focus on confidence intervals rather than p-values from statistical tests of significance is likely to be required.

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

**********

Acceptance letter

Meryem Merve Ören Çelik

8 Apr 2024

PONE-D-23-43186R1

PLOS ONE

Dear Dr. Kor,

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now being handed over to our production team.

At this stage, our production department will prepare your paper for publication. This includes ensuring the following:

* All references, tables, and figures are properly cited

* All relevant supporting information is included in the manuscript submission,

* There are no issues that prevent the paper from being properly typeset

If revisions are needed, the production department will contact you directly to resolve them. If no revisions are needed, you will receive an email when the publication date has been set. At this time, we do not offer pre-publication proofs to authors during production of the accepted work. Please keep in mind that we are working through a large volume of accepted articles, so please give us a few weeks to review your paper and let you know the next and final steps.

Lastly, if your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

If we can help with anything else, please email us at customercare@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Meryem Merve Ören Çelik

Academic Editor

PLOS ONE

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    S1 Appendix. The SPIRIT Checklist of the study.

    (DOCX)

    pone.0302235.s001.docx (38.1KB, docx)
    S2 Appendix. The informed consent form.

    (DOCX)

    pone.0302235.s002.docx (15.4KB, docx)
    S3 Appendix. The original study protocol approved by ethics committee.

    (PDF)

    pone.0302235.s003.pdf (835.4KB, pdf)
    S1 Fig. The PRIME theory of motivation.

    (TIF)

    pone.0302235.s004.tif (304.1KB, tif)
    S2 Fig. The mindful coping model.

    (TIF)

    pone.0302235.s005.tif (85.8KB, tif)
    Attachment

    Submitted filename: Response to Reviewers.docx

    pone.0302235.s006.docx (19KB, docx)

    Data Availability Statement

    No datasets were generated or analysed during the current study. All relevant data from this study will be made available upon study completion.


    Articles from PLOS ONE are provided here courtesy of PLOS

    RESOURCES